TY - JOUR
T1 - d-Sorbose Promotes Regulatory T-Cell Differentiation and Ameliorates Autoimmune and Allergic Diseases via Hexosamine Biosynthetic Pathway Inhibition
AU - Sato, Fumiaki
AU - Hoshi, Masato
AU - Yokoi, Hiroyuki
AU - Yoshida, Sayaka
AU - Takenaka, Ryosuke
AU - Shimoga, Nao
AU - Morita, Nanaka
AU - Tashita, Chieko
AU - Yamazaki, Kyoka
AU - Kishimoto, Yuka
AU - Tezuka, Hiroyuki
AU - Ito, Hiroyasu
AU - Saito, Kuniaki
N1 - Publisher Copyright:
© 2026 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
PY - 2026/9/15
Y1 - 2026/9/15
N2 - Monosaccharides are fundamental biomolecules involved in various biological processes. Rare sugars, naturally scarce monosaccharide derivatives, exhibit unique physiological effects independent of standard energy metabolism. Among them, d-sorbose, the C-3 epimer of d-fructose, has poorly understood biological functions. This study investigated the immunometabolic effects of d-sorbose, focusing on regulatory T-cell (Treg) differentiation and immune modulation. Ex vivo assays using splenic naïve CD4+ T cells revealed that d-sorbose significantly increased Foxp3+ Treg frequencies to levels comparable to d-mannose, without inducing the CD8+ T cell reduction observed with d-mannose. In vivo, continuous d-sorbose administration ameliorated ovalbumin-induced airway inflammation and prevented autoimmune diabetes in non-obese diabetic mice by selectively increasing interleukin-10-producing Tregs in regional lymph nodes and inflamed tissues. Histological analyses revealed reduced inflammatory cell infiltration and preserved tissue architecture in d-sorbose-treated groups. Metabolomic profiling indicated that d-sorbose suppressed glycolysis, the pentose phosphate pathway, and the hexosamine biosynthetic pathway (HBP), as evidenced by decreased UDP-GlcNAc levels, while elevating the tricarboxylic acid cycle intermediate malate. Pharmacological inhibition of glutamine–fructose-6-phosphate aminotransferase, combined with glutamine restriction and GlcNAc rescue assays, demonstrated that d-sorbose promotes Treg differentiation through coordinated metabolic reprogramming of glucose partitioning and glutamine catabolism rather than passive HBP inhibition. Notably, d-sorbose treatment did not alter T-cell survival and demonstrated a favorable safety profile during long-term administration. These findings identify d-sorbose as a novel immunoregulatory sugar that promotes functional Treg differentiation by orchestrating intracellular glucose and glutamine metabolism, highlighting its potential as a dietary or therapeutic agent for controlling inflammatory and autoimmune diseases.
AB - Monosaccharides are fundamental biomolecules involved in various biological processes. Rare sugars, naturally scarce monosaccharide derivatives, exhibit unique physiological effects independent of standard energy metabolism. Among them, d-sorbose, the C-3 epimer of d-fructose, has poorly understood biological functions. This study investigated the immunometabolic effects of d-sorbose, focusing on regulatory T-cell (Treg) differentiation and immune modulation. Ex vivo assays using splenic naïve CD4+ T cells revealed that d-sorbose significantly increased Foxp3+ Treg frequencies to levels comparable to d-mannose, without inducing the CD8+ T cell reduction observed with d-mannose. In vivo, continuous d-sorbose administration ameliorated ovalbumin-induced airway inflammation and prevented autoimmune diabetes in non-obese diabetic mice by selectively increasing interleukin-10-producing Tregs in regional lymph nodes and inflamed tissues. Histological analyses revealed reduced inflammatory cell infiltration and preserved tissue architecture in d-sorbose-treated groups. Metabolomic profiling indicated that d-sorbose suppressed glycolysis, the pentose phosphate pathway, and the hexosamine biosynthetic pathway (HBP), as evidenced by decreased UDP-GlcNAc levels, while elevating the tricarboxylic acid cycle intermediate malate. Pharmacological inhibition of glutamine–fructose-6-phosphate aminotransferase, combined with glutamine restriction and GlcNAc rescue assays, demonstrated that d-sorbose promotes Treg differentiation through coordinated metabolic reprogramming of glucose partitioning and glutamine catabolism rather than passive HBP inhibition. Notably, d-sorbose treatment did not alter T-cell survival and demonstrated a favorable safety profile during long-term administration. These findings identify d-sorbose as a novel immunoregulatory sugar that promotes functional Treg differentiation by orchestrating intracellular glucose and glutamine metabolism, highlighting its potential as a dietary or therapeutic agent for controlling inflammatory and autoimmune diseases.
KW - OVA-induced asthma model
KW - d-sorbose
KW - hexosamine biosynthetic pathway
KW - non-obese diabetes (NOD) model
KW - rare sugar
KW - regulatory T cell
UR - https://www.scopus.com/pages/publications/105048673818
UR - https://www.scopus.com/pages/publications/105048673818#tab=citedBy
U2 - 10.1096/fj.202601110R
DO - 10.1096/fj.202601110R
M3 - Article
C2 - 42664029
AN - SCOPUS:105048673818
SN - 0892-6638
VL - 40
JO - FASEB Journal
JF - FASEB Journal
IS - 17
M1 - e72252
ER -